Serum levels of MASP-1 before the treatment were significantly reduced in both P-LN patients (median 2865.30 ng/mL; IQR 2644.10, 3556.59 ng/mL) and non-LN patients (median 3836.70 ng/mL; IQR 3545.45, 4238.90 ng/mL) compared to NHCs (median 5111.26 ng/mL; IQR 3664.48, 7269.76 ng/mL). This evidence concerns the gene MASP1 and lobular neoplasia.